[ad_1]
According to Pfizer Novartis is the second pharmaceutical company to waive the surtaxes planned for the second semester and to congratulate the US president. "We are putting a lot of pressure on the potential decline in prescription drug prices," Trump said in a tweet to both companies yesterday, and himself. From the price drop, however, is nothing to see. Many other pharmaceutical companies have already raised their prices without being bothered by Trump. Novartis announced that it was the first country in terms of price transparency in California last June, according to Group CEO, Vas Narasimhan, namely that they would not raise prices before the end of the year. "We thought it would be wise considering the dynamic environment." The decision was indeed clever. Thanks to the president's favor, Novartis has gained a seat at the forefront of the debate on the future regulation of pharmaceutical prices.
Photos: Trump Praises Novartis
Trump had a program in May, "American Patients First" underlined and promised that large pharmaceutical companies would reduce prices "voluntarily massively" – in a few weeks. The claim has turned out to be an absurd invention, as expected. All pharmaceutical companies have been able to increase their prescription drug prices in the first half of the year as usual. In the case of Novartis, according to Wells Fargo, there were 75 drugs with a gain of 2.9% to 9.9%. With the exception of Novartis and Pfizer, manufacturers continued this practice during the second half of the year. Roche, Celgene and Novo Nordisk, for example, attracted attention with striking additions. The president's threats temporarily put pressure on the industry in the spring, but she recovered. Novartis (up eight per cent), Roche (up seven) and Pfizer (up four) have rallied since the end of May in response to significant gains in the US [19659007]. To remove Michael Cohen. The group hired the dubious Trump lawyer for $ 1.2 million, hoping to have direct access to the president with him. Cohen did not hold what he promised, and Novartis broke up with him. But the contacts obviously went further and lasted longer than we thought. Four Democratic senators revealed last week that Novartis may have been able to respond to price policy proposals in the Trump roadmap. Novartis denies it and considers that the case must be settled. But a final decision would be premature, because we do not know yet how much the price policy of Trump will be drastic.
Modest Effect
Pharmaceutical experts expect the industry to hold back until the end of the year, but stringent pricing rules will increase. Health Minister Alex Azar is expected to open the doors as he once ran the pharmaceutical company Eli Lilly. Presumably, the industry is also trying to avoid any fuss by raising prices that are no longer concentrated on January 1 and July 1, writes Ronny Gal, an analyst at Bernstein. In the end, the Novartis effect remains modest. "Everything will slow down for a moment, but sooner or later accelerate again."
(Tages-Anzeiger)
Date created: 19/07/2018, 21:37
Source link
